Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
0.2405
Dollar change
+0.0116
Percentage change
5.07
%
Index- P/E- EPS (ttm)-20.56 Insider Own0.00% Shs Outstand186.89M Perf Week31.06%
Market Cap47.23M Forward P/E- EPS next Y-14.11 Insider Trans- Shs Float186.89M Perf Month70.33%
Income-135.25M PEG- EPS next Q-3.90 Inst Own1.51% Short Float0.85% Perf Quarter63.05%
Sales11.29M P/S4.18 EPS this Y33.36% Inst Trans256.62% Short Ratio0.04 Perf Half Y-79.09%
Book/sh0.48 P/B0.50 EPS next Y23.09% ROA-115.46% Short Interest1.59M Perf Year-98.19%
Cash/sh0.14 P/C1.67 EPS next 5Y- ROE-138.69% 52W Range0.12 - 22.14 Perf YTD-98.14%
Dividend Est.- P/FCF- EPS past 5Y79.31% ROI-169.47% 52W High-98.91% Beta2.21
Dividend TTM- Quick Ratio2.78 Sales past 5Y0.00% Gross Margin-18.28% 52W Low103.81% ATR (14)0.02
Dividend Ex-Date- Current Ratio3.33 EPS Y/Y TTM-83.05% Oper. Margin-731.49% RSI (14)74.81 Volatility13.55% 14.41%
Employees103 Debt/Eq0.12 Sales Y/Y TTM183.05% Profit Margin-1197.86% Recom1.00 Target Price25.25
Option/ShortNo / Yes LT Debt/Eq0.08 EPS Q/Q87.46% Payout- Rel Volume1.16 Prev Close0.23
Sales Surprise-10.41% EPS Surprise94.07% Sales Q/Q-29.26% EarningsNov 12 BMO Avg Volume35.96M Price0.24
SMA2029.05% SMA5044.60% SMA200-91.06% Trades Volume41,684,612 Change5.07%
Date Action Analyst Rating Change Price Target Change
Apr-18-22Initiated Noble Capital Markets Outperform
Apr-18-19Upgrade ROTH Capital Neutral → Buy $4
Aug-18-17Upgrade ROTH Capital Neutral → Buy $6
Sep-07-16Downgrade ROTH Capital Buy → Neutral
Feb-17-16Reiterated Oppenheimer Outperform $18 → $10
Nov-04-15Initiated Cantor Fitzgerald Buy
Jun-12-15Initiated Oppenheimer Outperform $18
Feb-17-15Reiterated ROTH Capital Buy $10 → $12
Sep-29-14Reiterated ROTH Capital Buy $17 → $10
Dec-09-24 07:30AM
Dec-03-24 07:00AM
Nov-26-24 07:00AM
Nov-18-24 04:05PM
07:00AM
07:30AM Loading…
Nov-14-24 07:30AM
Nov-13-24 04:05PM
09:05AM
Nov-12-24 08:00AM
Nov-05-24 07:55AM
Nov-04-24 07:00AM
Nov-01-24 07:00AM
Oct-29-24 08:00AM
Oct-25-24 08:00AM
Oct-24-24 08:00AM
08:00AM Loading…
Oct-17-24 08:00AM
Oct-16-24 01:01PM
08:00AM
Oct-09-24 07:28AM
Oct-08-24 08:30AM
Oct-01-24 01:31PM
07:30AM
Sep-30-24 07:00AM
Sep-27-24 07:00AM
Sep-23-24 07:00AM
Sep-19-24 07:00AM
Sep-18-24 07:30AM
Sep-16-24 07:00AM
Sep-11-24 01:00PM
Sep-10-24 07:00AM
07:00AM Loading…
Sep-09-24 07:00AM
Sep-06-24 07:00AM
Sep-04-24 07:00AM
Aug-29-24 07:00AM
Aug-28-24 07:00AM
Aug-26-24 10:41AM
07:00AM
Aug-23-24 07:45AM
Aug-21-24 07:00AM
Aug-20-24 12:34PM
07:00AM
Aug-19-24 06:00AM
Aug-16-24 10:52PM
01:29PM
07:00AM
Aug-13-24 08:00AM
Aug-12-24 08:00AM
Aug-06-24 08:00AM
Aug-01-24 07:45AM
Jul-31-24 08:00AM
Jul-30-24 08:00AM
Jul-29-24 09:00AM
Jul-25-24 08:30AM
08:00AM
Jul-24-24 07:45AM
Jul-22-24 07:00AM
Jul-19-24 12:48PM
Jul-18-24 10:20AM
Jul-17-24 08:00AM
Jul-10-24 04:30PM
Jul-09-24 09:15AM
07:39AM
Jul-08-24 05:00PM
08:00AM
07:00AM
Jul-01-24 11:07AM
08:00AM
Jun-28-24 04:05PM
Jun-27-24 11:01AM
08:37AM
08:36AM
07:34AM
Jun-26-24 04:40PM
03:13PM
Jun-25-24 08:00AM
Jun-21-24 07:30AM
Jun-20-24 08:00AM
Jun-18-24 12:31PM
08:00AM
Jun-17-24 08:00AM
Jun-13-24 05:00PM
Jun-12-24 10:06AM
09:00AM
08:52AM
07:46AM
Jun-11-24 05:17PM
10:26AM
Jun-10-24 12:14PM
11:55AM
Jun-06-24 11:00AM
08:00AM
Jun-05-24 08:00AM
Jun-03-24 08:00AM
May-30-24 08:00AM
May-29-24 08:00AM
May-28-24 08:00AM
May-22-24 08:00AM
May-21-24 08:00AM
May-20-24 10:53AM
May-15-24 08:00AM
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.